

Long noncoding RNA lincRNA-p21 is the major mediator of UVB-induced and p53-dependent apoptosis in keratinocytes

JR Hall^{1,2,3}, ZJ Messenger^{1,3}, HW Tam^{1,3}, SL Phillips⁴, L Recio⁴ and RC Smart^{*1,2,3}

LincRNA-p21 is a long noncoding RNA and a transcriptional target of p53 and HIF-1 α . LincRNA-p21 regulates gene expression in *cis* and *trans*, mRNA translation, protein stability, the Warburg effect, and p53-dependent apoptosis and cell cycle arrest in doxorubicin-treated mouse embryo fibroblasts. p53 plays a key role in the response of skin keratinocytes to UVB-induced DNA damage by inducing cell cycle arrest and apoptosis. In skin cancer development, UVB-induced mutation of p53 allows keratinocytes upon successive UVB exposures to evade apoptosis and cell cycle arrest. We hypothesized that lincRNA-p21 has a key functional role in UVB-induced apoptosis and/or cell cycle arrest in keratinocytes and loss of lincRNA-p21 function results in the evasion of apoptosis and/or cell cycle arrest. We observed that lincRNA-p21 transcripts are highly inducible by UVB in mouse and human keratinocytes in culture and in mouse skin *in vivo*. LincRNA-p21 is regulated at the transcriptional level in response to UVB, and the UVB induction of lincRNA-p21 in keratinocytes and *in vivo* in mouse epidermis is primarily through a p53-dependent pathway. Knockdown of lincRNA-p21 blocked UVB-induced apoptosis in mouse and human keratinocytes, and lincRNA-p21 was responsible for the majority of UVB-induced and p53-mediated apoptosis in keratinocytes. Knockdown of lincRNA-p21 had no effect on cell proliferation in untreated or UVB-treated keratinocytes. An early event in skin cancer is the mutation of a single p53 allele. We observed that a mutant p53^{+R172H} allele expressed in mouse epidermis (K5Cre^{+tg};LSLp53^{+R172H}) showed a significant dominant-negative inhibitory effect on UVB-induced lincRNA-p21 transcription and apoptosis in epidermis. We conclude lincRNA-p21 is highly inducible by UVB and has a key role in triggering UVB-induced apoptotic death. We propose that the mutation of a single p53 allele provides a pro-oncogenic function early in skin cancer development through a dominant inhibitory effect on UVB-induced lincRNA-p21 expression and the subsequent evasion of UVB-induced apoptosis.

Cell Death and Disease (2015) 6, e1700; doi:10.1038/cddis.2015.67; published online 19 March 2015

The Human Genome Project revealed that only ~3% of human genome encodes protein.¹ The remaining 97% of the human genome is referred to as noncoding DNA. Initially, much of the intergenic noncoding sequence was referred to as 'junk DNA' as it was considered to have no function. Although some intergenic sequences contain DNA elements important in gene regulation, it is now known that many intergenic sequences can be transcribed into RNA.²⁻⁵ In fact, ~85% of the human genome is transcribed into RNA.^{6,7} RNA transcripts that lack protein-coding function are referred to as noncoding RNAs (ncRNAs) and of these the long ncRNAs (lncRNAs; ≥ 200 nt) represent the majority. Most lncRNAs are transcribed from intergenic or intronic regions of the genome or overlap with or are transcribed antisense to protein-coding genes.⁸ LncRNAs are one of the largest and more diverse classes of cellular transcripts with over 10 000 lncRNA transcripts reported in the human genome.^{6,7}

Only a handful of lncRNAs have been studied to date and mostly in cell culture. These lncRNAs are involved in

regulating gene expression through a variety of mechanisms including epigenetic silencing, transcriptional regulation, RNA processing, RNA modification and translation.^{4,9} Emerging evidence indicates that lncRNAs are associated with human diseases such as cancer,^{10,11} Alzheimer's¹² and heart disease.¹³ In lung, liver, prostate and breast cancer, the expression of certain lncRNAs correlates with tumor development, progression or survival.^{10,11} Half of all the trait-associated SNPs identified in GWAS are located in non-coding DNA intergenic sequences, and many of the intergenic regions may function by encoding lncRNAs.¹⁴ These results point to important roles of lncRNAs in human disease. It is critical to determine whether associations of lncRNAs with specific diseases are functionally significant and to develop mouse genetic models to define and characterize the function of lncRNAs in disease *in vivo*. LncRNAs could represent diagnostic markers and/or possible therapeutic targets. Moreover, because the etiology of most chronic human diseases involves interactions with the environment,¹⁵ it is important to

¹Department of Biological Sciences, North Carolina State University, Raleigh, NC, USA; ²Center for Human Health and the Environment, North Carolina State University, Raleigh, NC, USA; ³Toxicology Program, North Carolina State University, Raleigh, NC, USA and ⁴ILS, Research Triangle Park, NC, USA

*Corresponding author: RC Smart, Department of Biological Sciences, North Carolina State University, Campus Box 7633, Raleigh, NC 27695-7633, USA. Tel: +1 919 515 7245; Fax: +1 919 515 7169; E-mail: rcsmart@ncsu.edu

Abbreviations: lncRNA, long noncoding RNA; lincRNA, long intergenic noncoding RNA; NMSC, nonmelanoma skin cancer; UVB, ultraviolet B; SCC, squamous cell carcinoma; NHEK, normal human epidermal keratinocyte; K5, keratin 5; siRNA, small interfering RNA; FACS, fluorescent automated cell sorting; PI, propidium iodide; H&E, hematoxylin and eosin; FITC, fluorescein isothiocyanate; BrdU, bromodeoxyuridine; ncRNA, noncoding RNA; MEFs, mouse embryo fibroblasts; MEM, minimal erythema dose; GWAS, genome wide association studies

Received 17.9.14; revised 09.2.15; accepted 17.2.15; Edited by G Calin

determine whether environmental factors can impact the expression, activity and function of lincRNAs to contribute to disease pathogenesis.

Nonmelanoma skin cancer (NMSC) is the most common cancer in the United States.¹⁶ The majority of NMSCs is environmentally induced and caused by solar UVB radiation which produces DNA damage and mutations. Each year, there are more cases of NMSC than all cases of breast, prostate, lung and colon cancers combined. For skin squamous cell carcinomas (SCCs), the incidence of p53 mutations ranges from 50 to 90% in both humans and mice.^{17,18} UVB-induced mutation of p53 allows keratinocytes upon successive UVB exposures to evade apoptosis^{19–22} and cell cycle arrest.²³ These defects have a critical role in skin cancer development. Mice lacking one or both copies of p53 as well as mutant p53 mice all display increased susceptibility to UVB-induced skin cancer^{20,24–27} and greatly decreased apoptosis in response to UVB.^{19–22}

LincRNA-p21 is a long intergenic non-coding RNA (3100 nt).²⁸ Because of lincRNA-p21's location on chromosome 17, approximately 15 kb upstream from the *Cdkn1a* (p21) gene, it was named lincRNA-p21.²⁸ LincRNA-p21 was first reported to be a direct transcriptional target of p53 and to mediate p53-dependent apoptosis but not cell cycle arrest in doxorubicin-treated mouse embryo fibroblasts (MEFs).²⁸ Another more recent report indicates that lincRNA-p21 has no role in apoptosis and has an important role in regulating p53-dependent cell cycle arrest in doxorubicin-treated MEFs.²⁹ The former report²⁸ states that lincRNA-p21 regulates global gene expression in trans whereas the latter report²⁹ indicates that lincRNA-p21 only regulates nearby *Cdkn1a* (p21) in a *cis*

manner. Thus, there are conflicting reports on the role of lincRNA-p21 in MEFs. LincRNA-p21 can also regulate mRNA translation and protein stability.³⁰ Recently, lincRNA-p21 transcripts were shown to be upregulated in livers of mice treated with the carcinogen furan³¹ and lincRNA-p21 was shown to be hypoxia-responsive and promote glycolysis and regulate the Warburg effect independent of p53.³²

Because of the key role of p53 in UVB-induced apoptosis, cell cycle arrest and skin cancer, we reasoned that lincRNA-p21 could have a critical functional role in UVB-induced apoptosis and/or cell cycle arrest in keratinocytes and its loss in the evasion of apoptosis and/or defective cell cycle control and the pathogenesis of skin cancer. Our results reveal that lincRNA-p21 is highly inducible by UVB through a p53-dependent mechanism and that lincRNA-p21 has a key role in triggering UVB-induced apoptosis in human and mouse keratinocytes.

Results

LincRNA-p21 transcripts are highly inducible by UVB in mouse and human keratinocytes in culture and in mouse skin *in vivo*. Treatment of Balb/MK2 mouse keratinocytes with UVB radiation resulted in increased levels of p53 protein and its target gene, p21 (Figure 1a) demonstrating that Balb/MK2 keratinocytes are responsive to UVB radiation. To determine whether UVB radiation can increase lincRNA-p21 transcript levels, Balb/MK2 keratinocytes were treated with various doses of UVB radiation. UVB exposure was an potent inducer of lincRNA-p21 transcripts producing up to a ~60-fold increase in lincRNA-p21 (Figure 1b). UVB treatment




Figure 1 LincRNA-p21 (Linc-p21) transcripts are highly inducible by UVB in mouse and human keratinocytes in culture and in mouse skin. (a) Balb/MK2 mouse keratinocytes were exposed to UVB, collected 8 h later and immunoblot analysis conducted. (b) Balb/MK2 mouse keratinocytes were exposed to the indicated doses of UVB, collected 16 h later and lincRNA-p21 transcript levels measured. (c) Balb/MK2 cells were exposed to 10 mJ/cm² UVB and lincRNA-p21 transcript levels measured at the indicated times. (d) NHEK cells were exposed to the indicated doses of UVB, collected 16 h later and lincRNA-p21 transcripts measured. (e) NHEK cells were exposed to 10 mJ/cm² UVB and lincRNA-p21 transcripts measured at the indicated times. (f) SKH-1 mice (three mice per time point) were exposed to 100 or 200 mJ/cm² UVB, epidermis was collected at 9 h and lincRNA-p21 levels measured. (g) SKH-1 mice (three mice per group) were treated with 100 mJ/cm² and lincRNA-p21 transcripts measured at the indicated times. LincRNA-p21 levels were measured by TaqMan real-time PCR (Ct value at peak post UVB = 26–29 cycles using 25 ng template for all experiments). LincRNA-p21 was normalized to β -actin. Data are expressed as the mean \pm S.D. $N \geq 3$, * $P < 0.05$ significantly different compared with time 0 using student *t*-test

increased lincRNA-p21 in a dose-dependent manner (Figure 1b). Time-course studies revealed that UVB increased lincRNA-p21 levels as early as 4 h post UVB treatment with peak transcript levels occurring at ~16 h (Figure 1c). Normal human epidermal keratinocytes (NHEK) also displayed a UVB dose-dependent induction of lincRNA-p21 (Figure 1d) and a similar time course and magnitude of induction of lincRNA-p21 (~50-fold) (Figure 1e) as mouse keratinocytes. To determine whether UVB radiation was capable of inducing lincRNA-p21 *in vivo* in skin (epidermis), we utilized SKH-1 hairless mice and environmentally relevant doses of UVB. SKH-1 mice are an experimental model used to study the effects of UVB in skin and are relevant to UVB-induced human SCC skin cancer as the UV-induced tumors in these mice resemble, both at the morphologic and molecular levels, the UVB-induced SCC skin cancers in humans.³³ The minimal erythema dose (MED) of UVB treatment in skin is defined as the minimal dose that produces a just-perceptible erythema (redness) at 24 h. SKH-1 mice were treated with UVB doses that correspond to 0.5 (100 mJ/cm²) and 1.0 MED (200 mJ/cm²). LincRNA-p21 was highly inducible by UVB radiation in SKH-1 mouse epidermis *in vivo* (Figures 1f and g). Collectively, these data demonstrate that lincRNA-p21 transcripts are highly inducible by UVB in mouse and human keratinocytes in culture and in mouse skin *in vivo*.

LincRNA-p21 is transcriptionally upregulated in response to UVB and is p53-dependent in keratinocytes in culture and in mouse skin *in vivo*. To determine whether lincRNA-p21 is regulated at the transcriptional level in response to UVB treatment, we treated Balb/MK2 keratinocytes with actinomycin D, an inhibitor of transcription, and then exposed the cells to UVB and collected the cells 12 h later. As shown in Figure 2a, actinomycin D blocked the increase in UVB-induced lincRNA-p21 transcripts indicating that lincRNA-p21 is regulated at the transcriptional level in response to UVB treatment. Next, we examined the role of p53 on the regulation of UVB-induced lincRNA-p21 expression in Balb/MK2 keratinocytes in culture. UVB-treated p53 knockdown keratinocytes (Figure 2b) were significantly impaired in their ability to induce lincRNA-p21 transcripts (Figure 2c). Next, we examined the role of p53 on the regulation of UVB-induced lincRNA-p21 expression *in vivo* in mouse epidermis using K5Cre^{+tg};p53^{fllox/fllox} mice. In this mouse model, the keratin 5 (K5) promoter directs Cre recombinase expression to the epidermis.³⁴ UVB-treated K5Cre^{+tg};p53^{fllox/fllox} mice SKH-1 mice lacking p53 in their epidermis (Figure 2d) displayed significantly decreased levels of epidermal lincRNA-p21 transcripts compared with UVB-treated K5Cre^{+tg} mice (Figure 2e). Although the majority (~85%) of UVB-induced lincRNA-p21 in mouse skin *in vivo* occurs through a p53-dependent pathway, there also appears to be a minor




Figure 2 LincRNA-p21 is regulated at the transcriptional level and is p53-dependent in mouse and human keratinocytes and mouse skin *in vivo*. (a) Balb/MK2 keratinocytes were treated with actinomycin D, exposed to 10 mJ/cm² UVB, collected 12 h later and lincRNA-p21 transcripts measured. (b) Balb/MK2 cells were transfected with siRNA to p53 or control siRNA, and 48 h post transfection, cells were exposed to 10 mJ/cm² UVB, collected 12 h later and p53 protein levels were measured by immunoblot analysis. (c) Balb/MK2 cells were transfected with siRNA to p53 or control siRNA, and 48 h post transfection, cells were exposed to 10 mJ/cm² UVB, collected 12 h later and lincRNA-p21 transcripts measured. (d) K5Cre^{+tg} and K5Cre^{+tg};p53^{fllox/fllox} SKH-1 mice were treated with 200 mJ/cm² UVB and epidermis collected 9 h later and p53 protein levels were measured by immunoblot analysis. (e) K5Cre^{+tg} and K5Cre^{+tg};p53^{fllox/fllox} mice were treated with 200 mJ/cm² UVB and epidermis collected 9 h later and lincRNA-p21 transcripts measured. (f) MT2.5, MT2.6 and Balb/MK2 cells were exposed to 10 mJ/cm² UVB and collected 8 h later. (g) NHEK and HaCaT cells were exposed to 10 mJ/cm² UVB and collected 12 h later. LincRNA-p21 transcript levels were determined by TaqMan real-time PCR. Expression of lincRNA-p21 was normalized to β-actin. Data expressed in a, c, e, f and g as the mean ± S.D. N ≥ 3, *P < 0.05 significantly different compared to UVB exposed control as determined by the student t-test

(~15%) p53-independent pathway involved in the UVB regulation of lincRNA-p21 transcript levels (Figures 2e). We also observed that mouse skin SCC lines that are defective in p53 signaling (MT2.5 and MT2.6)³⁵ were unable to induce lincRNA-p21 in response to UVB radiation compared with mouse keratinocytes (Figure 2f). Likewise, HaCaT cells which are a spontaneously immortalized human keratinocyte cell line that contain two alleles of mutant p53³⁶ also displayed significantly impaired UVB induction of lincRNA-p21 when compared with similarly treated NHEKs (Figure 2g). Collectively, these data demonstrate that lincRNA-p21 is regulated at the transcriptional level in response to UVB treatment and that the UVB induction of lincRNA-p21 in keratinocytes and *in vivo* in mouse epidermis is dependent upon p53.

LincRNA-p21 is a critical regulator of apoptosis in UVB-treated mouse and human keratinocytes. To begin to determine the functional role of lincRNA-p21 in UVB-treated keratinocytes, we used an siRNA approach to knockdown lincRNA-p21. As shown in Figure 3a, we were able to knockdown lincRNA-p21 transcript levels in UVB-treated mouse keratinocytes by >80% using two different siRNA sequences.²⁶ Knockdown of lincRNA-p21 had no effect on cell viability in untreated keratinocytes (Figure 3b); however, UVB-treated lincRNA-p21-depleted keratinocytes displayed an increased viability (Figure 3c). These results suggest that in UVB-treated keratinocytes, lincRNA-p21 functions to inhibit keratinocyte cell cycle progression and/or to induce keratinocyte apoptosis in response to UVB. Earlier studies showed

that lincRNA-p21 has an important role in regulating p53-dependent cell cycle arrest involving p21 in doxorubicin-treated MEFs.²⁹ Therefore, we first examined the levels of p53 and p21 in control and lincRNA-p21-depleted keratinocytes and observed that the levels of p53 and p21 were not affected by the knockdown of lincRNA-p21 (Figure 3d). These results indicate that the knockdown of lincRNA-p21 does not interfere with p53 protein levels or the regulation of p21 in response to UVB. In accord with these results, the knockdown of lincRNA-p21 had no effect on the cell cycle distribution and the DNA damage checkpoint as determined by FACS analysis (Figures 3e and f). In contrast to the lack of effect on cell proliferation and DNA damage checkpoint function, lincRNA-p21-depleted keratinocytes displayed striking decreases in UVB-induced apoptosis as determined by decreased cleaved caspase-3 levels (Figure 4a) and decreased annexin-V staining (Figure 4b). On the basis of annexin V single positive staining, there was a ~10-fold decrease in early apoptotic cells in lincRNA-p21-depleted keratinocytes at 18 h post UVB (Figure 4b). Similar results were obtained with a second lincRNA-p21 siRNA sequence (Figure 4c). These data demonstrate that lincRNA-p21 is a critical regulator of UVB-induced apoptosis and regulates at least 75% of the apoptosis induced by UVB in mouse keratinocytes (Figures 4b and c). Knockdown of lincRNA-p21 resulted in altered expression of several genes associated with apoptosis in response to UVB radiation indicating that lincRNA-p21 can both repress the expression of anti-apoptotic and activate the expression of pro-apoptotic genes in response to UVB (Figure 4d). The levels of *Cdkn1a* mRNA




Figure 3 LincRNA-p21 (linc-p21) does not regulate cell proliferation in UVB-treated keratinocytes. (a) Balb/MK2 cells were transfected with siRNA to lincRNA-p21 or control siRNA, and 48 h post transfection, cells were exposed to 10 mJ/cm² UVB, collected 18 h later and lincRNA-p21 transcripts measured. (b) Control siRNA and lincRNA-p21 #1 knockdown Balb/MK2 cells were counted at 0, 24 and 48 h post transfection. (c) Control and lincRNA-p21 #1 knockdown Balb/MK2 cells were exposed to 10 mJ/cm² UVB (48 h post transfection, *t* = 0), and cells were counted 24 and 48 h after UVB (*N* = 3 for each time point). (d) Control and lincRNA-p21 #1 knockdown Balb/MK2 cells were exposed to 10 mJ/cm² UVB (48 h post transfection) and collected 18 h after UVB and immunoblot analysis conducted. (e) Control and lincRNA-p21 #1 knockdown Balb/MK2 cells were exposed to 10 mJ/cm² UVB (48 h post transfection) and collected 24 h after UVB, PI-stained and analyzed by FACS. (f) Control and lincRNA-p21 #1 and #2 knockdown Balb/MK2 cells were exposed to 10 mJ/cm² UVB (48 h post transfection) and pulse-labeled with BrdU for 1 h and collected 6 h after UVB. Cells were stained with BrdU-FITC and PI-stained and analyzed by FACS. Data expressed in a, b, c, e and f as the mean ± S.D. *N* ≥ 3, **P* < 0.05 significantly different compared with UVB-exposed control as determined by the student *t*-test




Figure 4 LincRNA-p21 (linc-p21) regulates apoptosis in UVB-treated keratinocytes. (a) Control and lincRNA-p21 #1 knockdown Balb/MK2 cells were exposed to 10 mJ/cm² UVB (48 h post transfection) and collected at 0, 8 and 18 h after UVB exposure and immunoblot analysis for caspase 3 conducted; results shown are representative of duplicate experiments. (b) Control and lincRNA-p21 #1 knockdown Balb/MK2 cells were exposed to 10 mJ/cm² UVB (48 h post transfection) and collected at 0, 6, 12, 18 and 24 h after UVB. Cells were stained with annexin-V and PI and analyzed by FACS. Similar results were obtained in three independent experiments. (c) Control and lincRNA-p21 #1 and #2 knockdown Balb/MK2 cells were exposed to 10 mJ/cm² UVB (48 h post transfection) and 24 h after UVB. Cells were stained with annexin-V and PI and analyzed by FACS. Similar results were obtained in three independent experiments. (d) Control and lincRNA-p21 #1 and #2 knockdown Balb/MK2 cells were exposed to 10 mJ/cm² and collected at 18 h post UVB and candidate gene expression examined by Taqman RT-PCR. (e) Control and lincRNA-p21 #1 and #2 knockdown Balb/MK2 cells were exposed to 10 mJ/cm² and collected at 18 h post UVB and immunoblot analysis conducted. (f) NHEK cells were transfected with siRNA to human lincRNA-p21 or control siRNA, 48 h later exposed to 10 mJ/cm² UVB, collected 18 h later and lincRNA-p21 levels measured. (g) Control and lincRNA-p21 knockdown NHEK cells were exposed to 10 mJ/cm² UVB (48 h post transfection) and collected at 0 and 18 h after UVB. Cells were stained with annexin-V and PI and analyzed by FACS. Similar results were obtained in three independent experiments. (h) Control and lincRNA-p21 knockdown NHEK cells were exposed to 10 mJ/cm² and collected at 18 h post UVB, and candidate gene expression examined. Data are expressed in **c**, **d**, **f**, **g** and **h** as the mean \pm S.D. $N \geq 3$, * $P < 0.05$ significantly different compared with siRNA control as determined by the student *t*-test

were not decreased by knockdown of lincRNA-p21 in UVB-treated keratinocytes; in fact, there was an unexpected ~two fold increase. Additionally, the protein levels of the proapoptotic factors Noxa and Bax were significantly reduced in lincRNA-p21 knockdown cells following UVB exposure and despite changes in Stat3 mRNA, no changes in Stat3 protein were observed (Figure 4e). Next, we examined the role of lincRNA-p21 in UVB-induced apoptosis in human keratinocytes. The knockdown of human lincRNA-p21 in NHEKs

(Figure 4f) resulted in decreased apoptosis as determined by annexin V staining (Figure 4g). Thus, lincRNA-p21 is a key mediator of UVB-induced apoptosis in human keratinocytes and is responsible for ~70% of UVB-induced apoptosis (Figure 4g). Knockdown of lincRNA-p21 in NHEKs resulted in the altered expression of apoptosis-related genes in response to UVB; lincRNA-p21 represses the expression of anti-apoptotic genes and activates the expression of proapoptotic genes in response to UVB and had no effect on

CDKN1A mRNA levels (Figure 4h). These data reveal that lincRNA-p21 has a major and critical role in UVB-induced apoptotic death in human and mouse keratinocytes.

Mutant p53^{+R172H} allele displays a significant dominant-negative inhibitory effect on UVB-induced lincRNA-p21 transcription and apoptosis in epidermis. Because the development of UVB-induced skin cancer often entails early oncogenic events involving the mutation of a single p53 allele and the escape from UVB-induced apoptosis, we examined whether a dominant inhibitory mutation in a single p53 allele (p53^{+R172H}) could greatly impair UVB-induced lincRNA-p21 transcript levels and apoptosis when compared with loss-of-function mutation involving deletion of a single p53 allele (p53^{+/-}). Previous studies have shown that missense mutants of p53 in the heterozygous state can function as dominant-negative inhibitors of certain tumor-suppressive functions and retain normal wild-type p53 of others.^{37,38} For example, in p53^{+R172H} cells, the mutant p53 does not have a dominant-negative effect on DNA damage-induced G₁ arrest or p21 gene expression but does have a dominant-negative effect on gamma radiation-induced apoptosis.³⁸ Therefore, we generated two genetically engineered mouse models (K5Cre^{+tg};p53^{+flox} and K5Cre^{+tg};LSLp53^{+R172H})^{38,39} to test whether the mutation of a single p53 allele (p53^{+R172H}) as opposed to the loss of a single p53 allele (p53^{+/-}), both expressed under normal physiological control *in vivo* in epidermis of SKH-1 mice, will have a dominant-negative effect on UVB-induced lincRNA-p21 expression and keratinocyte apoptosis. In this mouse model, the keratin 5 (K5) promoter directs Cre recombinase expression to the epidermis.³⁴ As shown in Figure 5a, UVB-induced lincRNA-p21 levels in K5Cre^{+tg};LSLp53^{+R172H} mice were greatly decreased and were similar to the levels in K5Cre^{+tg};p53^{flox/flox} mice whereas lincRNA-p21 transcript levels in K5Cre^{+tg} and K5Cre^{+tg};p53^{+flox} were similar. These results demonstrate a potent effect of the dominant inhibitory mutation of a p53 allele (p53^{+R172H}) on UVB-induced lincRNA-p21 transcript levels. Next, we examined whether the decreased levels of lincRNA-p21 transcripts in UVB-treated K5Cre^{+tg};LSLp53^{+R172H} are associated with decreased p53-

dependent apoptosis induced by UVB. As shown in Figure 5b, approximately 50% of UVB-induced apoptosis in mouse epidermis is dependent on p53. UVB-induced apoptosis was similarly decreased in K5Cre^{+tg};p53^{flox/flox} and K5Cre^{+tg};LSLp53^{+R172H} mice indicating that the mutation in a single p53 allele (p53^{+R172H}) has a significant dominant-negative inhibitory effect on lincRNA-p21 transcription and apoptosis *in vivo*. These data further suggest that deregulation of lincRNA-p21 expression may be important in the early pro-oncogenic functions of p53 mutant keratinocytes during the development of skin cancer.

Discussion

In sun-exposed areas of the human skin, p53 plays an important role in skin cancer prevention through its regulation of keratinocyte cell cycle arrest and apoptosis in response to UVB radiation-induced DNA damage.^{17,19–24,40} These p53-regulated responses serve to prevent UVB-induced mutagenesis by producing cell cycle arrest to allow time for DNA repair and by triggering apoptotic death of DNA-damaged keratinocytes. We have identified lincRNA-p21 as the key mediator of UVB-induced apoptosis in human and mouse keratinocytes. Our results demonstrate that p53 plays a key role in regulating lincRNA-p21 transcript levels in response to UVB in keratinocytes and that lincRNA-p21 has a critical function in triggering apoptosis in UVB-treated keratinocytes. In fact, lincRNA-p21 is responsible for the majority of UVB-induced apoptosis in both human and mouse keratinocytes.

Several lncRNAs have been shown to be regulated by p53 or to modulate apoptosis in response to DNA damage, for example, Pint⁴¹ and Panda⁴² have anti-apoptotic activity, whereas INXS,⁴³ MEG3,⁴⁴ lincRNA-p21²⁸ and Gas5⁴⁵ all have pro-apoptotic activity. It is generally considered that p53-regulated lncRNAs serve to fine tune p53-regulated apoptosis and/or cell cycle arrest and function as low copy number lncRNAs. Our results indicate that lincRNA-p21 does much more than fine tune the p53 response in UVB-treated keratinocytes as lincRNA-p21 is responsible for the majority of UVB-induced and p53-mediated apoptosis. LincRNA-p21 is regulated at the transcriptional level in response to UVB and the UVB induction of lincRNA-p21 in keratinocytes and *in vivo*




Figure 5 Mutation of single p53 allele has a dominant-negative effect *in vivo* in mouse epidermis. (a) K5Cre^{+tg}, K5Cre^{+tg};LSLp53^{+R172H}, K5Cre^{+tg};p53^{+flox} and K5Cre^{+tg};p53^{flox/flox} SKH-1 mice were treated with 200 mJ/cm² UVB and epidermal lincRNA-p21 transcripts measured 9 h post UVB treatment. (b) K5Cre^{+tg}, K5Cre^{+tg};LSLp53^{+R172H}, K5Cre^{+tg};p53^{+flox} and K5Cre^{+tg};p53^{flox/flox} SKH-1 mice were treated with 100 mJ/cm² UVB and the number of apoptotic interfollicular basal epidermal keratinocytes/cm skin were scored at 9 h post UVB treatment. Data are expressed as the mean \pm S.D. $N \geq 3$, * $P < 0.05$ significantly different compared with UVB-treated K5Cre mice as determined by the student

in mouse epidermis is primarily through a p53-dependent pathway. We observed that UVB is an extremely potent inducer of lincRNA-p21, producing ~50–60-fold increase in mouse and human keratinocytes. Thus, lincRNA-p21 transcript levels rise from low copy number of transcripts to very significant transcript levels in response to UVB to trigger apoptotic keratinocyte death. Evaluation of candidate gene expression in UVB-treated keratinocytes revealed that lincRNA-p21 represses the expression of anti-apoptotic genes Mcl1, Stat3 and Atf2 and activates the expression of pro-apoptotic genes Noxa and Bax. Future studies are required to understand how lincRNA-p21 is repressing and activating gene expression in keratinocytes in response to UVB treatment.

As mentioned in the 'Introduction', there are conflicting reports on the functional role for lincRNA-p21 in MEFs. Huarte *et al.*²⁸ reported that lincRNA-21 functions as the global *trans* regulator of gene expression, has no effect on p21 expression and mediates p53-dependent apoptosis but not cell cycle arrest in doxorubicin-treated MEFs. On the other hand, Dimitrova *et al.*²⁹ report lincRNA-p21 does not regulate apoptosis but regulates p53-mediated cell cycle arrest through the regulation of p21 in *cis* in doxorubicin-treated MEFs and that lincRNA-p21 indirectly regulates genes associated the Polycomb Repressive Complex 2 through a p21-dependent mechanism. A major technical difference between these studies is that Huarte *et al.*²⁸ used an RNAi knockdown approach and Dimitrova *et al.*²⁹ employed knockout MEFs. Dimitrova *et al.* suggested that this difference in depleting lincRNA-p21 could be responsible for the different cellular outcomes. Our results agree with the findings of Huarte *et al.*²⁸ and like their study, our studies utilized an RNAi knockdown approach. We found lincRNA-p21 has a key role in regulating UVB- and p53-mediated apoptosis in both human and mouse keratinocytes using three different RNAis. These results argue against off-target effects and further studies in lincRNA-p21 knockout keratinocytes will be required to address method of depletions and whether lincRNA-p21 functions in *cis* or *trans* to regulate gene expression in UVB-treated keratinocytes.

Depletion of lincRNA-p21 allows keratinocytes to evade UVB-induced apoptosis suggesting a possible tumor suppressor function for lincRNA-p21 in NMSC. In skin cancer, the incidence of p53 mutations ranges from 50 to 90% in humans and mice.^{17,18} Mutant p53 provides keratinocytes an advantage over normal keratinocytes in response to successive UVB exposure by evading cell cycle checkpoints and by allowing mutant keratinocytes to evade UVB-induced apoptosis.^{17,19–23,40} These events promote genomic instability, clonal expansion and the development of skin cancer. In early skin cancer development, a single p53 allele is mutated or deleted as an early initiating oncogenic event.¹⁷ Patches/clones of mutant p53 keratinocytes (considered to be the precursor lesion to skin cancer) can be detected in sun-exposed areas of human skin and in UVB-treated mouse skin long before tumors form.^{17,46,47} Most of these clones have a single mutant allele of p53 (97% missense and 3% non-sense).¹⁷ Collectively, these studies indicate that mutation of a single p53 allele provides a pro-oncogenic function/advantage early in skin cancer development. Our results demonstrate a potent dominant-negative inhibitory effect of a single mutant

p53 allele (p53^{+/R172H}) on UVB-induced lincRNA-p21 transcript levels and UVB-induced apoptosis. We propose that the mutation of a single p53 allele provides a pro-oncogenic function early in skin cancer development through a dominant inhibitory effect on UVB-induced lincRNA-p21 expression and the subsequent evasion of UVB-induced apoptosis.

The etiology of most chronic human diseases involves complex interactions among environmental factors and an individual's genetic and epigenetic makeup. However, these gene × environment interactions are poorly understood, leading to a deficit in our understanding of how these interactions contribute to adverse health outcomes. Our study demonstrates for the first time that exposure to an environmental factor, in this case solar UVB radiation, can impact the expression, activity and function of a lincRNA. Moreover, lincRNA-p21 expression is induced *in vivo* in mouse skin by environmentally relevant doses of UVB. We speculate that lincRNA-p21 may function as a tumor suppressor gene in UVB-induced non-melanoma skin cancer where the loss of lincRNA-p21 expression results in the evasion of apoptosis.

Materials and Methods

Cells and mice. Balb/MK2 keratinocytes were a gift from B. E. Weissman (UNC)⁴⁸ are maintained in Ca²⁺-free EMEM (Lonza, Walkersville, MD, USA), 8% Chelax-treated FBS (F2442, Sigma Aldrich, St. Louis, MO, USA), 4 ng/ml hEGF (Life Technologies, Carlsbad, CA, USA) and 0.05 mM CaCl₂⁴⁶ NHEKs were purchased from Lonza and maintained in KGM-Gold keratinocyte medium (Lonza). 129S-p53LSL.R172H (LSLp53^{+/R172H}) mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA).³⁸ FVB.129-Trp53^{tm1Bm} (p53^{fllox/fllox}) were obtained through the NCI Mouse Repository.³⁹ To generate SKH-1 mice, LSLp53^{+/R172H} and p53^{fllox/fllox} male mice were mated to SKH-1 (Charles River Labs, Wilmington, MA, USA) females. Male LSLp53^{+/R172H} and p53^{fllox/fllox} males were backcrossed to SKH-1 females five times to obtain SKH-1 LSLp53^{+/R172H} and p53^{fllox/fllox} SKH-1 mice. K5Cre, K5Cre;LSLp53^{+/R172H}, K5Cre;p53^{+/fllox} and K5Cre;p53^{fllox/fllox} littermates that were used in this study were obtained by crossing LSLp53^{+/R172H} and p53^{+/fllox} SKH-1 female mice with K5Cre;LSLp53^{+/R172H} and K5Cre;p53^{+/fllox} SKH-1 male mice. K5Cre mice were a gift from Angel Ramirez and Jose Jorcano³⁴ and detailed information on control (K5Cre^{+/lg}) SKH-1 mice have been described.⁵⁰ All aspects of animal care and experimentation described in this study were conducted according to the NIH guidelines and approved by the Institutional Animal Care and Use Committee of NCSU.

UVB treatment and chemicals. Balb/MK2 keratinocytes were exposed at less than 50% confluence to 10 mJ/cm² UVB with a calibrated UVB lamp as previously described.⁴⁹ SKH-1 mice were treated with a single dose of 100 or 200 mJ/cm² UVB as described.⁵⁰

Small interfering RNA. siRNA targeting mouse p53 (5'-AGAAGAAAU UCCGCAAAdTdT-3'), mouse lincRNA-p21 #1 (5'-UGAAAAGAGCCGUGAGC UAdTdT-3'),²⁶ mouse lincRNA-p21 #2 (5'-AAATAAAGATGGTGGAATGdT-3'), human lincRNA-p21 (5'-CUGCAAGGCCGCAUGAUGAdTdT-3') and the negative control (GFP, 5'-GGCUACGUCCAGGAGCGCACCdT-3') were synthesized by Life Technologies and transfected at the final concentration of 100 nM. All transfections were performed using DharmaFECT Reagent 1 (GE Healthcare, Little Chalfont, UK) according to the manufacturer's recommendations. Cells were exposed to UVB 48 h post siRNA transfection.

Preparation of epidermal lysates and nuclear cell extracts. Mice were killed by cervical dislocation and dorsal skin was removed and subjected to 6 s heat shock in 60 °C dH₂O followed by 10 s in ice water. Epidermis was isolated and RNA was purified as described below. Protein lysates were prepared in RIPA buffer (1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 1 mM dithiothreitol, 1 mM sodium orthovanadate, 1 mM AEBF, and 1 × protease inhibitor cocktail (Roche, Indianapolis, IN, USA) in PBS. Lysates were sonicated and centrifuged at 14 000 × g for 10 min. Equal protein was resolved by SDS-PAGE.

Antibodies. Antibodies against p21 (sc-471) and Bax (sc-493) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Noxa antibody (ab13654) was purchased from Abcam (Cambridge, UK). p53 antibody (1C12) was purchased from Cell Signaling (Danvers, MA, USA). β -Actin antibody (A5441) was purchased from Sigma Aldrich. Caspase-3 antibody (CS-9665S) and cleaved caspase-3 (Cleaved Caspase-3 (CS-9661S)) were purchased from Cell Signaling and generously provided by Dr. Jun Tsuji (NCSU).

RNA and quantitative PCR. Total RNA was isolated using QiaZOL lysis (Qiagen, Valencia, CA, USA), and further purified using Qiagen RNeasy columns. cDNA was prepared from RNA by ImProm-II Reverse Transcription System (Promega, Madison, WI, USA). Quantitative PCR for mouse LincRNA-p21 (FAM probe TGGCCAAACACTGGTG, forward primer GAAGCTTCTTGGTGTAG ATCAAAA, reverse primer CCACACCAGGTAGAACTACGAAA) and human LincRNA-p21 (FAM probe ATGCGGCCTTGCAGG, forward primer CCCGGCCTTGTCTTTTGT, reverse primer GAGTGGGTGGCTCACTCTTCTG) was performed using Custom TaqMAN Gene Expression Assays (Life Technologies).³¹ Additional mouse TaqMAN RT-PCR assays include p53 Mm441964_g1, Gapdh Mm9999915_g1, β -Actin Mm00607939_s1, Noxa Mm00451763_m1, Atf2 Mm00833804_g1, Survivin Mm00599749_m1, Mcl1 Mm00725832_s1, Bax Mm00432051_m1, Puma Mm00519268_m1, Cdkn1a Mm00432448_m1 and Stat3 Mm01219775_m1. Additional human TaqMAN RT-PCR assays include GAPDH Hs33929097_g1, β -Actin Hs99999903_m1, NOXA Hs00560402_m1, ATF2 Hs01095345_m1, CDKN1A Hs00355782_m1 and STAT3 Hs01047580_m1 (Life Technologies). TaqMan Gene Expression Assays were used in combination with FastStart Universal Probe Master Mix (Roche). Data were analyzed using the comparative $\Delta\Delta C_T$ method.

Detection of apoptotic keratinocytes. H&E-stained mouse skin sections were used to quantify the presence of apoptotic keratinocytes. As previously described, apoptotic keratinocytes in the interfollicular basal epidermis were scored positive if all three of the following criteria were present: dark pyknotic nuclei, cytoplasmic eosinophilia and absence of cellular contacts.⁵¹ Data are presented as the average number of apoptotic interfollicular basal epidermal keratinocytes/cm skin.

BrdU staining. Cells were pulsed-labeled with 10 μ M BrdU for 1 h before collection. Harvested cells were washed twice with ice-cold PBS and then fixed by the addition of ice-cold 75% ethanol. Staining with anti-BrdU FITC was performed as previously described.⁴⁷ Cells were analyzed by flow cytometry at the NCSU Flow Cytometry and Cell Sorting Laboratory.

Annexin-V staining. Harvested cells were washed twice with ice-cold PBS and then resuspended in Annexin V Binding Buffer (BioLegend, San Diego, CA, USA) at a concentration of 1×10^6 cells per ml. Five microliters of Annexin V Pacific Blue was added to 100 μ l of the cell suspension, followed by the addition of 10 μ l propidium iodide (PI) solution (BioLegend). Cells were incubated for 15 min at room temperature in the dark, followed by the addition of 400 μ l Annexin V Binding Buffer. Cells were analyzed by flow cytometry at the NCSU Flow Cytometry and Cell Sorting Laboratory. Data were collected and presented on a scatter plot with Annexin V Pacific Blue intensity on the x axis and PI intensity on the y axis.

Statistical analysis. Differences between groups were evaluated by two-sided *t*-tests for paired data with the significance level set to $P < 0.05$.

Conflict of Interest

The authors declare no conflicts of interest.

Acknowledgements. This research was supported by grants from the National Institute of Environmental Health Sciences (ES017734 to JRH, ES12473 awarded to RCS, and ZJM was supported by training grant ES007046). Additional support for this research was provided by a NC State University Center for Human Health and Environment pilot project grant awarded to JRH and RCS.

1. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J *et al*. Initial sequencing and analysis of the human genome. *Nature* 2001; **409**: 860–921.

2. Bertone P, Stolc V, Royce TE, Rozowsky JS, Urban AE, Zhu X *et al*. Global identification of human transcribed sequences with genome tiling arrays. *Science* 2004; **306**: 2242–2246.
3. Kapranov P, Cheng J, Dike S, Nix DA, Duttaputra R, Willingham AT *et al*. RNA maps reveal new RNA classes and a possible function for pervasive transcription. *Science* 2007; **316**: 1484–1488.
4. Mattick JS. The genetic signatures of noncoding RNAs. *PLoS Genet* 2009; **5**: e1000459.
5. Mercer TR, Gerhardt DJ, Dinger ME, Crawford J, Trapnell C, Jeddelloh JA *et al*. Targeted RNA sequencing reveals the deep complexity of the human transcriptome. *Nat Biotechnol* 2012; **30**: 99–104.
6. Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A *et al*. Landscape of transcription in human cells. *Nature* 2012; **489**: 101–108.
7. Hangauer MJ, Vaughn IW, McManus MT. Pervasive transcription of the human genome produces thousands of previously unidentified long intergenic noncoding RNAs. *PLoS Genet* 2013; **9**: e1003569.
8. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. *Cell* 2009; **136**: 629–641.
9. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. *Mol Cell* 2011; **43**: 904–914.
10. Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. *RNA Biol* 2012; **9**: 703–719.
11. Prensner JR, Chinnaiyan AM. The emergence of lincRNAs in cancer biology. *Cancer Discov* 2011; **1**: 391–407.
12. Faghghi MA, Modarresi F, Khalil AM, Wood DE, Sahagan BG, Morgan TE *et al*. Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. *Nat Med* 2008; **14**: 723–730.
13. Papat R, Kunderfranco P, Stirparo GG, Latronico MV, Condorelli G. Long noncoding RNA: a new player of heart failure? *J Cardiovasc Transl Res* 2013; **6**: 876–883.
14. Hindorf LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS *et al*. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. *Proc Natl Acad Sci USA* 2009; **106**: 9362–9367.
15. Sears ME, Genies SJ. Environmental determinants of chronic disease and medical approaches: recognition, avoidance, supportive therapy, and detoxification. *J Environ Public Health* 2012; **2012**: 356798.
16. Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB *et al*. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. *Arch Dermatol* 2010; **146**: 283–287.
17. Kramata P, Lu YP, Lou YR, Singh RN, Kwon SM, Conney AH. Patches of mutant p53-immunoreactive epidermal cells induced by chronic UVB irradiation harbor the same p53 mutations as squamous cell carcinomas in the skin of hairless SKH-1 mice. *Cancer Res* 2005; **65**: 3577–3585.
18. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P *et al*. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. *Hum Mutat* 2007; **28**: 622–629.
19. Tron VA, Trotter MJ, Tang L, Krajewska M, Reed JC, Ho VC *et al*. p53-regulated apoptosis is differentiation dependent in ultraviolet B-irradiated mouse keratinocytes. *Am J Pathol* 1998; **153**: 579–585.
20. Wijnhoven SW, Speksnijder EN, Liu X, Zwart E, van Oostrom CT, Beems RB *et al*. Dominant-negative but not gain-of-function effects of a p53.R270H mutation in mouse epithelium tissue after DNA damage. *Cancer Res* 2007; **67**: 4648–4656.
21. Wikonkal NM, Remenyik E, Knezevic D, Zhang W, Liu M, Zhao H *et al*. Inactivating E2f1 reverts apoptosis resistance and cancer sensitivity in Trp53-deficient mice. *Nat Cell Biol* 2003; **5**: 655–660.
22. Ziegler A, Jonason AS, Leffell DJ, Simon JA, Sharma HW, Kimmelman J *et al*. Sunburn and p53 in the onset of skin cancer. *Nature* 1994; **372**: 773–776.
23. Maeda T, Chong MT, Espino RA, Chua PP, Cao JQ, Chomey EG *et al*. Role of p21(Waf-1) in regulating the G1 and G2/M checkpoints in ultraviolet-irradiated keratinocytes. *J Invest Dermatol* 2002; **119**: 513–521.
24. Jiang W, Ananthaswamy HN, Muller HK, Kripke ML. p53 protects against skin cancer induction by UV-B radiation. *Oncogene* 1999; **18**: 4247–4253.
25. Li G, Ho VC, Berean K, Tron VA. Ultraviolet radiation induction of squamous cell carcinomas in p53 transgenic mice. *Cancer Res* 1995; **55**: 2070–2074.
26. Li G, Tron V, Ho V. Induction of squamous cell carcinoma in p53-deficient mice after ultraviolet irradiation. *J Invest Dermatol* 1998; **110**: 72–75.
27. van Kranen HJ, Westerman A, Berg RJ, Kram N, van Kreijl CF, Wester PW *et al*. Dose-dependent effects of UVB-induced skin carcinogenesis in hairless p53 knockout mice. *Mutat Res* 2005; **571**: 81–90.
28. Huarte M, Guttman M, Feldser D, Garber M, Koziol MJ, Kenzelmann-Broz D *et al*. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. *Cell* 2010; **142**: 409–419.
29. Dimitrova N, Zamudio JR, Jong RM, Soukup D, Resnick R, Sarma K *et al*. LincRNA-p21 activates p21 in cis to promote polycomb target gene expression and to enforce the G1/S checkpoint. *Mol Cell* 2014; **54**: 777–790.
30. Yoon JH, Abdelmohsen K, Srikanth S, Yang X, Martindale JL, De S *et al*. LincRNA-p21 suppresses target mRNA translation. *Mol Cell* 2012; **47**: 648–655.

31. Recio L, Phillips SL, Maynor T, Waters M, Jackson AF, Yauk CL. Differential expression of long noncoding RNAs in the livers of female B6C3F1 mice exposed to the carcinogen furan. *Toxicol Sci* 2013; **135**: 369–379.
32. Yang F, Zhang H, Mei Y, Wu M. Reciprocal regulation of HIF-1 α and lincRNA-p21 modulates the Warburg effect. *Mol Cell* 2014; **53**: 88–100.
33. Benavides F, Oberszyn TM, VanBuskirk AM, Reeve VE, Kusewitt DF. The hairless mouse in skin research. *J Dermatol Sci* 2009; **53**: 10–18.
34. Ramirez A, Page A, Gandarillas A, Zanet J, Pibre S, Vidal M *et al*. A keratin K5Cre transgenic line appropriate for tissue-specific or generalized Cre-mediated recombination. *Genesis* 2004; **39**: 52–57.
35. Shim M, Powers KL, Ewing SJ, Zhu S, Smart RC. Diminished expression of C/EBP α in skin carcinomas is linked to oncogenic Ras and reexpression of C/EBP α in carcinoma cells inhibits proliferation. *Cancer Res* 2005; **65**: 861–867.
36. Lehman TA, Modali R, Boukamp P, Stanek J, Bennett WP, Welsh JA *et al*. p53 mutations in human immortalized epithelial cell lines. *Carcinogenesis* 1993; **14**: 833–839.
37. Aurelio ON, Kong XT, Gupta S, Stanbridge EJ. p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines. *Mol Cell Biol* 2000; **20**: 770–778.
38. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT *et al*. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. *Cell* 2004; **119**: 847–860.
39. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. *Nat Genet* 2001; **29**: 418–425.
40. Brash DE. Sunlight and the onset of skin cancer. *Trends Genet* 1997; **13**: 410–414.
41. Marin-Bejar O, Marchese FP, Athie A, Sanchez Y, Gonzalez J, Segura V *et al*. Pint lincRNA connects the p53 pathway with epigenetic silencing by the Polycomb repressive complex 2. *Genome Biol* 2013; **14**: R104.
42. Hung T, Wang Y, Lin MF, Koegel AK, Kotake Y, Grant GD *et al*. Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. *Nat Genet* 2011; **43**: 621–629.
43. DeOcesano-Pereira C, Amaral MS, Parreira KS, Ayupe AC, Jacysyn JF, Amarante-Mendes GP *et al*. Long non-coding RNA INXS is a critical mediator of BCL-XS induced apoptosis. *Nucleic Acids Res* 2014; **42**: 8343–8355.
44. Zhou Y, Zhong Y, Wang Y, Zhang X, Batista DL, Gejman R *et al*. Activation of p53 by MEG3 non-coding RNA. *J Biol Chem* 2007; **282**: 24731–24742.
45. Mourtada-Maarabouni M, Pickard MR, Hedge VL, Farzaneh F, Williams GT. GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. *Oncogene* 2009; **28**: 195–208.
46. Berg RJ, van Kranen HJ, Rebel HG, de Vries A, van Vloten WA, Van Kreijl CF *et al*. Early p53 alterations in mouse skin carcinogenesis by UVB radiation: immunohistochemical detection of mutant p53 protein in clusters of preneoplastic epidermal cells. *Proc Natl Acad Sci USA* 1996; **93**: 274–278.
47. Jonason AS, Kunala S, Price GJ, Restifo RJ, Spinelli HM, Persing JA *et al*. Frequent clones of p53 keratinocytes in normal human skin. *Proc Natl Acad Sci USA* 1996; **93**: 14025–14020.
48. Weissman BE, Aaronson SA. BALB and Kirsten murine sarcoma viruses alter growth and differentiation of EGF-dependent balb/c mouse epidermal keratinocyte lines. *Cell* 1983; **32**: 599–606.
49. Yoon K, Smart RC. C/EBP α is a DNA damage-inducible p53-regulated mediator of the G1 checkpoint in keratinocytes. *Mol Cell Biol* 2004; **24**: 10650–10660.
50. Thompson EA, Zhu S, Hall JR, House JS, Ranjan R, Burr JA *et al*. C/EBP α expression is downregulated in human nonmelanoma skin cancers and inactivation of C/EBP α confers susceptibility to UVB-induced skin squamous cell carcinomas. *J Invest Dermatol* 2011; **131**: 1339–1346.
51. Ewing SJ, Zhu S, Zhu F, House JS, Smart RC. C/EBP β represses p53 to promote cell survival downstream of DNA damage independent of oncogenic Ras and p19(Arf). *Cell Death Differ* 2008; **15**: 1734–1744.



Cell Death and Disease is an open-access journal published by **Nature Publishing Group**. This work is licensed under a **Creative Commons Attribution 4.0 International License**. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>